NCT03595813Completed
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy-IMMUNO-SUP-IPC 2017-002
Source: ClinicalTrials.gov · Last updated 21 Apr 2026
Brief summary (registry, in English)
The development of Immune Checkpoint Blockade (ICB) is a revolution in medical oncology as ICB have changed the standard treatments of several metastatic tumor types. However, the response rate to ICB is low, and the biological bases for this response heterogeneity are poorly understood. In the frame of Immunosup study, we will collect blood (at baseline, post infusion of ICB n°2/4/8 and at progression) and tumor samples (optional: at baseline and progression) from patients with locally advanced or metastatic cancer, treated with ICB, in order to determine if the dynamics of immunosuppressive actors (MDSC, TReg, Immunosuppressive cytokines) predicts response to these immunotherapies.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 135 (actual)
- First submitted
- 11 Jul 2018
- Start date
- 29 Jan 2018
- Primary completion date
- 17 Jul 2020
- Lead sponsor
- Institut Paoli-Calmettes
- Diseases
- Lung cancer
- NCT number
- NCT03595813
What you commit to
- Study type: Interventional
- Participants enrolled: 135
- From 29 Jan 2018 to the primary completion date, 17 Jul 2020
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Pregnant or breastfeeding woman or woman who does not apply effective contraception
- Emergency
- Vulnerable person or unable to provide informed consent
- Emergency
- Person unable to comply with required study follow up
- Contraindication to the study procedure
Who the study is looking for
- Age \> 18 years
- Diagnosis of locally advanced or metastatic solid tumor or lymphoma treated with Immune check blockade
- Signed informed consent
- Affiliated to(or beneficiary of) the French Social Security
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Paoli-Calmettes Coordinator of this site? Confirm its status | Marseille | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.